Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43182 | 0.88 | ALDH1A1 (0.44) | ALDH1A1MAPTKMT2ANPC1RAB9A | |
| Acetaldehyde SCHEMBL27849991 | 0.80 | KIF11 (0.50) | KIF11CYP2C9PTPN5ALDH1A1MAPT | |
| SCHEMBL9679722 | 0.80 | ALDH1A1 (0.41) | KIF11ALDH1A1MAPTKMT2ANPC1 | |
| Biphenyl SCHEMBL27538626 | 0.78 | ALDH1A1 (0.47) | KIF11CYP2C9PTPN5ALDH1A1MAPT | |
| SCHEMBL10806930 | 0.76 | KIF11 (0.52) | KIF11CYP2C9PTPN5ALDH1A1MAPT | |
| SCHEMBL4926591 | 0.75 | TSHR (0.50) | KIF11CYP2C9ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL128222 | 0.75 | KIF11 (0.59) | KIF11CYP2C9PTPN5ALDH1A1NPC1 | |
| SCHEMBL15832876 | 0.75 | ALDH1A1 (0.58) | KIF11CYP2C9PTPN5ALDH1A1MAPK1 | |
| SCHEMBL3421942 | 0.75 | KIF11 (0.59) | KIF11CYP2C9PTPN5ALDH1A1NPC1 | |
| SCHEMBL4558928 | 0.75 | KIF11 (0.42) | KIF11CYP2C9PTPN5ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12011425-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11760755-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11738019-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-11596611-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3426245-B1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11236111-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210283077-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-07-29 | — | — | US | disclosed |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20090131343-A1 | USE OF BRIDGED MACROLIDES OR TYLOSIN DERIVATIVES IN TREATING INFLAMMATORY BOWEL DISEASES | ENANTA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090053175-A1 | SUBSTITUTE PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047247-A1 | Pyrrolidine Derivatives | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090004140-A1 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | KIF11 1775/4885CYP2C9 11/4885PTPN5 2212/4885 |
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885CYP2C9 462/4885PTPN5 557/4885 |
| US-11236111-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | KIF11 3074/4885CYP2C9 685/4885PTPN5 1220/4885 |
| US-11596611-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885CYP2C9 462/4885PTPN5 557/4885 |
| US-11760755-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | KIF11 3074/4885CYP2C9 685/4885PTPN5 1220/4885 |
| US-20090004140-A1 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | EIF2AK2, RNGTT, POLR2E | KIF11 3942/4885CYP2C9 280/4885PTPN5 701/4885 |
| US-20090131343-A1 | USE OF BRIDGED MACROLIDES OR TYLOSIN DERIVATIVES IN TREATING INFLAMMATORY BOWEL DISEASES | TNF, SLC10A2, TMSB4X | KIF11 3584/4885CYP2C9 1149/4885PTPN5 2186/4885 |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ZC3HAV1, HAVCR2, HCCS | KIF11 3569/4885CYP2C9 597/4885PTPN5 885/4885 |
| US-20090053175-A1 | SUBSTITUTE PYRROLIDINE DERIVATIVES | POLRMT, EIF2AK2, NSUN2 | KIF11 3831/4885CYP2C9 511/4885PTPN5 588/4885 |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885CYP2C9 462/4885PTPN5 557/4885 |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | KIF11 3795/4885CYP2C9 1/4885PTPN5 1465/4885 |
| US-12011425-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885CYP2C9 462/4885PTPN5 557/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | KIF11 1122/4885CYP2C9 10/4885PTPN5 1653/4885 |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | KIF11 1284/4885CYP2C9 15/4885PTPN5 1753/4885 |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | KIF11 4285/4885CYP2C9 243/4885PTPN5 1169/4885 |
| US-20210283077-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885CYP2C9 462/4885PTPN5 557/4885 |
| US-11738019-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | KIF11 4285/4885CYP2C9 243/4885PTPN5 1169/4885 |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | EIF2AK2, ZC3HAV1, POLRMT | KIF11 3637/4885CYP2C9 705/4885PTPN5 1496/4885 |
| US-20090047247-A1 | Pyrrolidine Derivatives | ZC3HAV1, EIF2AK2, POLRMT | KIF11 3590/4885CYP2C9 530/4885PTPN5 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.